Iniparib administered weekly or twice-weekly in combination with gemcitabine/carboplatin in patients with metastatic triple-negative breast cancer: a phase II randomized open-label study with pharmacokinetics

被引：0
作者：
Véronique Diéras
Hervé Bonnefoi
Emilio Alba
Ahmad Awada
Bruno Coudert
Xavier Pivot
Joseph Gligorov
Agnes Jager
Stefania Zambelli
Geoffrey J. Lindeman
Eric Charpentier
Gary T. Emmons
Ignacio Garcia-Ribas
Robert Paridaens
Jaap Verweij
机构：
[1] Institut Curie,Department of Medical Oncology
[2] Centre Eugène Marquis,Department of Clinical Oncology
[3] Institut Bergonié,Oncology Medicine Department
[4] Univ. Bordeaux,Medical Oncology Department
[5] INSERM U1218,Department of Medical Oncology
[6] INSERM CIC1401,Medical Oncology Dept Tenon Hospital, Inserm U938
[7] Hospital Clínico Universitario Virgen de la Victoria,Department of Medical Oncology
[8] Institut Jules Bordet,Department of Medical Oncology
[9] Université Libre de Bruxelles,Department of Medical Oncology, Peter MacCallum Cancer Centre and Royal Melbourne Hospital
[10] Centre Georges François Leclerc,Statistics Department
[11] Centre Paul Strauss,Translational Medicine and Early Development
[12] Institut Universitaire de Cancérologie APHP-Sorbonne Université,Early Oncology Development
[13] Erasmus MC Cancer Institute,Department of Medical Oncology
[14] IRCCS OSR,undefined
[15] San Raffaele,undefined
[16] The Walter and Eliza Hall Institute of Medical Research,undefined
[17] Sanofi,undefined
[18] Sanofi,undefined
[19] Sanofi,undefined
[20] University Hospital Gasthuisberg,undefined
[21] Catholic University of Leuven,undefined
来源：
Breast Cancer Research and Treatment | 2019年 / 177卷
关键词：
Iniparib; Metastatic triple-negative breast cancer; Pharmacokinetics; Administration schedule;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：383 / 393
页数：10
相关论文
共 56 条
[1]  
Howlader N(2014)US incidence of breast cancer subtypes defined by joint hormone receptor and HER2 status J Natl Cancer Inst 295 2492-2502
[2]  
Altekruse SF(2006)Race, breast cancer subtypes, and survival in the Carolina Breast Cancer Study JAMA 13 4429-4434
[3]  
Li CI(2007)Triple-negative breast cancer: clinical features and patterns of recurrence Clin Cancer Res 115 423-428
[4]  
Carey LA(2009)Pattern of metastatic spread in triple-negative breast cancer Breast Cancer Res Treat 118 5463-5472
[5]  
Perou CM(2012)Clinicopathologic features, patterns of recurrence, and survival among women with triple-negative breast cancer in the National Comprehensive Cancer Network Cancer 28 3271-3277
[6]  
Livasy CA(2010)Metastatic behavior of breast cancer subtypes J Clin Oncol 9 29-33
[7]  
Dent R(2009)Survival outcomes for patients with metastatic triple-negative breast cancer: implications for clinical practice and trial design Clin Breast Cancer 24 628-637
[8]  
Trudeau M(2018)Carboplatin in BRCA1/2-mutated and triple-negative breast cancer BRCAness subgroups: the TNT Trial Nat Med 377 523-533
[9]  
Pritchard KI(2018)Atezolizumab and nab-paclitaxel in advanced triple-negative breast cancer N Engl J Med 379 753-763
[10]  
Dent R(2017)Olaparib for metastatic breast cancer in patients with a germline BRCA mutation N Engl J Med 18 510-523
123456